We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+12.86%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$158M
AUM Growth
-$7.14M
Cap. Flow
-$21.7M
Cap. Flow %
-13.81%
Top 10 Hldgs %
5.64%
Holding
474
New
40
Increased
153
Reduced
231
Closed
49

Top Buys

Rank Stock Value
1
EXPE icon
Expedia Group
EXPE
+$752K
2
IT icon
Gartner
IT
+$681K
3
TT icon
Trane Technologies
TT
+$681K
4
ETN icon
Eaton
ETN
+$660K
5
PLD icon
Prologis
PLD
+$658K

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$854K
2
AJG icon
Arthur J. Gallagher & Co
AJG
+$778K
3
IEX icon
IDEX
IEX
+$731K
4
TSLA icon
Tesla
TSLA
+$719K
5
YUMC icon
Yum China
YUMC
+$714K

Sector Composition

Rank Sector Weight
1 Healthcare 22.36%
2 Technology 15.51%
3 Financials 14.54%
4 Industrials 9.65%
5 Energy 8.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
176
DELISTED
Apellis Pharmaceuticals
APLS
$374K 0.24%
6,251
+2,950
+89% +$150K
FOLD
177
DELISTED
Amicus Therapeutics
FOLD
$372K 0.24%
26,201
+3,324
+15% +$37.7K
CION icon
178
CION Investment
CION
$298M
$368K 0.23%
32,533
-9,315
-22% -$99K
BBIO icon
179
BridgeBio Pharma
BBIO
$16.5B
$367K 0.23%
9,084
-8,934
-50% -$268K
ADMA icon
180
ADMA Biologics
ADMA
$1.97B
$365K 0.23%
80,743
+2,519
+3% +$9.32K
ACAD icon
181
Acadia Pharmaceuticals
ACAD
$4.35B
$364K 0.23%
11,625
-980
-8% -$23.4K
BPMC
182
DELISTED
Blueprint Medicines
BPMC
$359K 0.23%
3,892
-1,287
-25% -$83.4K
ITCI
183
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$358K 0.23%
4,994
+271
+6% +$15.6K
AXSM icon
184
Axsome Therapeutics
AXSM
$12.3B
$354K 0.22%
4,452
+690
+18% +$46.1K
NBIX icon
185
Neurocrine Biosciences
NBIX
$17.7B
$354K 0.22%
2,688
-539
-17% -$62K
INSM icon
186
Insmed
INSM
$22.7B
$350K 0.22%
11,295
-4,482
-28% -$116K
RYTM icon
187
Rhythm Pharmaceuticals
RYTM
$7.28B
$349K 0.22%
7,597
-9,596
-56% -$303K
IMCR icon
188
Immunocore
IMCR
$1.72B
$349K 0.22%
5,104
-161
-3% -$8.37K
MAIN icon
189
Main Street Capital
MAIN
$5B
$348K 0.22%
8,054
-3,095
-28% -$126K
DCF
190
DELISTED
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
DCF
$348K 0.22%
42,673
-22,420
-34% -$176K
TARS icon
191
Tarsus Pharmaceuticals
TARS
$2.62B
$345K 0.22%
+17,061
New +$285K
LGND icon
192
Ligand Pharmaceuticals
LGND
$5.96B
$344K 0.22%
4,818
+914
+23% +$53.9K
SWTX
193
DELISTED
SpringWorks Therapeutics
SWTX
$343K 0.22%
9,406
+5,816
+162% +$152K
ASND icon
194
Ascendis Pharma A/S
ASND
$16.6B
$342K 0.22%
2,716
-652
-19% -$65K
AMGN icon
195
Amgen
AMGN
$203B
$340K 0.22%
1,181
-198
-14% -$53.9K
TVTX icon
196
Travere Therapeutics
TVTX
$5.27B
$340K 0.22%
37,798
+19,817
+110% +$144K
RARE icon
197
Ultragenyx Pharmaceutical
RARE
$2.65B
$340K 0.22%
7,105
+1,033
+17% +$40K
EXEL icon
198
Exelixis
EXEL
$14B
$336K 0.21%
13,994
-2,207
-14% -$48K
KNSA icon
199
Kiniksa Pharmaceuticals
KNSA
$4.89B
$336K 0.21%
19,132
+671
+4% +$11K
ALNY icon
200
Alnylam Pharmaceuticals
ALNY
$37.2B
$335K 0.21%
1,749
+216
+14% +$36.8K
6 7
8
9 10

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q4 2023 Portfolio in Review

As of Q4 2023, Virtus ETF Advisers held 474 positions worth $158M, down 4.3% from $165M the previous quarter. Its ten largest holdings account for 5.6% of the portfolio.

Virtus ETF Advisers withdrew a net $21.7M in Q4 2023, closing 49 positions and reducing 231 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $854K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Financials.

Against the trend, Virtus ETF Advisers opened a new position in Expedia Group worth $932K.

  • Virtus ETF Advisers's largest Q4 2023 buy was Expedia Group: 6,139 shares worth $932K.
  • Virtus ETF Advisers added most to Pioneer Natural Resource Co. in Q4 2023, an estimated $535K increase.
  • Virtus ETF Advisers's biggest Q4 2023 reduction was VICI Properties, cutting an estimated $659K.
  • Virtus ETF Advisers fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $854K.
  • Virtus ETF Advisers's ten largest holdings make up 5.6% of its $158M portfolio in Q4 2023.
  • Virtus ETF Advisers opened 40 new positions and closed 49 in Q4 2023.
  • Virtus ETF Advisers's portfolio value fell 4.3% quarter-over-quarter to $158M.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.